Most Recent
The maker of Mother energy drinks has won an appeal of an IP Australia decision, succeeding in its bid to prevent a Victoria-based company from registering Kangaroo Mother as a trade mark for beverages.
Novartis has lost its bid to have Pharmacor’s claim that its patent for a blood pressure drug is invalid decided ahead of a main trial where the Swiss pharmaceutical giant will allege the generic drug maker is threatening to infringe its patent.
IP Australia has rejected US fintech Block's bid to patent a method for adjusting animations to enable a large volume of point of sale applications, finding the invention was a mere scheme that did not meet the manner of manufacture test for patentability.
A Coalition MP has urged the government to take action on the regulation of artificial intelligence, flagging “very significant” issues in the intellectual property sphere.
An IP Australia delegate has shot down Kraft's opposition to a Mars patent for a less costly method for producing the distinct creaminess and flavour of crumb chocolate.
After winning a rare injunction restraining the owners of a patent from threatening litigation, carparking technology company UbiPark has prevailed in its claim the threats -- aimed at itself and its customers -- were unjustified.
The security sum sought by Monster Energy from an inventor suing the beverage giant for patent infringement was "manifestly excessive", a judge has said, and was based on an estimate of costs that included the fees of three solicitors and two barristers at an interlocutory hearing.
Just days before trial, exercise bike giant Peloton Interactive has dropped its lawsuit against California fitness company Mad Dogg Athletics that sought removal of Mad Dogg's 'spinning' trade mark.
A judge has ordered the owner of vitamin brand Life Botanics to refrain from “vilifying, denigrating, disparaging or mocking” rival JSHealth, owned by influencer Jessica Sepel.
A judge has upheld findings from IP Australia that South Korean biotech ToolGen's genome editing technology CRISPR is not patentable, but given the company one more chance to seek to amend its application.